 SOMERVILLE, Mass., Aug. 10, 2021 GLOBE NEWSWIRE -- Finch Therapeutics Group, Inc. Finch or Finch Therapeutics Nasdaq: FNCH, a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today reported financial results for the second quarter ended June 30, 2021 and provided a business update. 